LAB Stock Alert

Halper Sadeh LLC Is Investigating Whether the Merger of Standard BioTools Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. is fair to Standard BioTools shareholders. Under the terms of the agreement, SomaLogic shareholders will receive 1.11 shares of Standard BioTools common stock for each share of SomaLogic common stock owned. Upon closing of the proposed transaction, Standard BioTools shareholders will own approximately 43% of the combined company.

Halper Sadeh encourages Standard BioTools shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

The investigation concerns whether Standard BioTools and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Standard BioTools shareholders; and (2) disclose all material information necessary for Standard BioTools shareholders to adequately assess and value the merger consideration. On behalf of Standard BioTools shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Standard BioTools shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231004042880/en/

The Standard BioTools Stock at the time of publication of the news with a fall of -20,37 % to 2,150EUR on Nasdaq stock exchange (04. Oktober 2023, 17:45 Uhr).